Story thread · 4 reports / 4 sources
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
seekingalpha.com · 6d
First report: Inhibrx targets OX40 agonist-cancer vaccine studies from early next year — endpts.com, 6d
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.